Based on the XBiotech Inc stock forecast from 0 analysts, the average analyst target price for XBiotech Inc is not available over the next 12 months. XBiotech Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of XBiotech Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, XBiotech Inc’s stock price was USD 3.36. XBiotech Inc’s stock price has changed by +7.01% over the past week, +3.38% over the past month and -66.03% over the last year.
No recent analyst target price found for XBiotech Inc
No recent average analyst rating found for XBiotech Inc
Company Overview XBiotech Inc
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas. Read Less
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also d...Read More
Frequently Asked Questions About XBiotech Inc (XBIT) Stock
Stock Target Advisor's fundamental analysis for XBiotech Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on XBIT's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on XBIT's stock to indicate what its average analyst target is.
XBIT stock's Price/Earning ratio is 1.17.
Our analysis grades XBIT stock's Price / Earning ratio at D+. This means that XBIT stock's Price/Earning ratio is above 31.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this XBIT may be fairly valued for its sector
The last closing price of XBIT's stock was USD 3.36.
The most recent market capitalization for XBIT is USD 0.09B.
Unfortunately we do not have enough analyst data on XBIT's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains XBiotech Inc's stock.
As per our most recent records XBiotech Inc has 92 Employees.
XBiotech Inc's registered address is 5217 Winnebago Lane, Austin, TX, United States, 78744.
You can get more information about it from XBiotech Inc's website at https://www.xbiotech.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About XBiotech Inc (XBIT) Stock
Stock Target Advisor's fundamental analysis for XBiotech Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on XBIT's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on XBIT's stock to indicate what its average analyst target is.
XBIT stock's Price/Earning ratio is 1.17.
Our analysis grades XBIT stock's Price / Earning ratio at D+. This means that XBIT stock's Price/Earning ratio is above 31.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this XBIT may be fairly valued for its sector
The last closing price of XBIT's stock was USD 3.36.
The most recent market capitalization for XBIT is USD 0.09B.
Unfortunately we do not have enough analyst data on XBIT's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains XBiotech Inc's stock.
As per our most recent records XBiotech Inc has 92 Employees.
XBiotech Inc's registered address is 5217 Winnebago Lane, Austin, TX, United States, 78744.
You can get more information about it from XBiotech Inc's website at https://www.xbiotech.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for XBIT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
